for a detailed description of the criteria.)
• However, no previous research has evaluated the validity of the algorithm.
In this study, we assessed the agreement of the case-finding algorithm with pathology data from the HealthCore Integrated Research Environment (HIRE SM ) -Oncology database.
OBJECTIVE
• To evaluate the accuracy of the Duh et al case-finding algorithm in identifying SCLC and NSCLC patients among patients diagnosed with lung cancer in a claims-database.
METHODS

Patient Selection Criteria
• Patients with lung cancer were selected from the HIRE -Oncology database, which combines U.S. administrative claims data with clinical oncology data (type, stage, etc).
• The index event was defined as the patient's first lung cancer diagnosis during 6/1/14 through 1/31/15 in the claims database (ICD-9-CM diagnosis codes 162.2 -162.9 and 231.2).
• Eligibility criteria were age ≥18 years, ≥1 lung cancer diagnosis, >12 months continuous pre-index enrollment in the claims database, and presence in the clinical oncology database.
Duh Case-Finding Algorithm Scoring
• In its original application, Duh et al developed the case-finding algorithm to identify SCLC cases within claims databases that included both SCLC and NSCLC.
-Inclusion criteria consisted of chemotherapy regimens applied to SCLC patients as recommended by the ACS and NCCN.
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-Exclusion criteria included tests and chemotherapies used for NSCLC patients as recommended by the ACS and NCCN.
• In our application, we reversed the roles of the inclusion and exclusion criteria.
-Inclusion criteria consisted of tests and chemotherapies used for NS-CLC patients as recommended by the ACS and NCCN.
-Exclusion criteria included chemotherapy regimens applied to SCLC patients as recommended by the ACS and NCCN.
• Three scoring systems were evaluated for the NSCLC case-finding algorithm.
-Method 1: Sum the number of NSCLC inclusion criteria (tests and treatments patients had received) based upon their claims data, and any patient with a score of ≥1 was classified as NSCLC.
-Method 2: Sum the number of SCLC exclusion criteria (SCLC recommended treatments patients had received) based upon their claims data, and any patient with a score of ≥1 was classified as SCLC and excluded.
-Method 3: A combination approach in which SCLC patients were excluded first, and then of the remaining patients, those meeting at ≥1 NSCLC criteria were classified as NSCLC.
Classification Criterion
• The pathology status for NSCLC versus SCLC contained within the HIRE -Oncology database was used as the analysis criterion.
Demographics and Comorbid Status
• Table 2 presents the demographic characteristics and comorbid illnesses for the study sample categorized as NSCLC and SCLC based on the pathology data.
• The whole study sample contained 585 lung cancer patients (mean age (SD), 62 (8.9); 53% male) who met all eligibility criteria for study.
RESULTS
STATISTICAL ANALYSIS
• Receiver operating curve (ROC) comparative analysis was used to select the better-performing scoring system among the three possible scoring methods.
• Diagnostic accuracy of the better-performing algorithm was assessed using the following statistical measures: sensitivity, specificity, positive predictive validity (PPV), negative predictive validity (NPV), false positive fraction (FPF), False Discovery Rate (FDR), Positive Likelihood Ratio (LR+), Negative Likelihood Ratio (LR-), Diagnostic Odds Ratio (DOR), and agreement using kappa (ϰ). Poster presentation at the ISPOR 18th Annual European Congress November 7 -11, 2015, Milan, Italy • The major strength of the algorithm is that it has strong sensitivity for identifying NSCLC patients in a database consisting of patients with SCLC and NSCLC.
• The major deficiency is poor specificity and low LR-. There are too many false positives. This is likely due to outdated criteria used in the NSCLC inclusion criteria.
• Future research should focus on updating the algorithm with newer treatments that have been approved for these specific types of lung cancers.
• In order to reduce the risk of including SCLC patients in claims-based epidemiologic and outcome studies focused on NSCLC, future research should focus on improving the algorithm's specificity.
LIMITATIONS
• The study criterion used to classify lung cancer patients into the NSCLC and SCLC categories was based on pathology findings, which are the standard of care, despite some misclassification error.
• Some of the study sample had limited post-diagnosis follow-up time that constrained their exposure to the SCLC and NSCLC treatment used in the algorithm. 
ROC Analysis Results
• Figure 1 presents the results of the ROC comparison among the 3 scoring methods. There was a significant difference in the classification accuracy of the 3 scoring methods.
• The SCLC exclusion criteria were superior to the NSCLC inclusion criteria in classification accuracy.
• There was no statistically significant difference between the combined inclusion/exclusion criteria and the SCLC exclusion criteria alone.
• The SCLC exclusion criteria scoring method was used for further analyses, since the combined inclusion/exclusion scoring system did not add significant classification accuracy. The area under the curve (AUC) for the SCLC exclusion scoring system was = 0.69 (95% confidence interval [CI], 0.64 -0.73), which is rated as good.
Classification Accuracy
• Table 3 shows the 2-way table for the NSCLC algorithm's predicted classification by the HIRE -Oncology pathology criterion results.
-Overall classification accuracy was 84.44%, which provides a 5.12% increment over simply categorizing all lung cancer patients as NSCLC (79.32%).
• The agreement rate between the algorithm and the pathology classification was 85.6%, expected agreement = 73.4%, and chance adjusted ϰ = 0.46 (Z = 12.13, P ≤ 0.0001). This is within the moderate agreement range.
• Table 4 shows the results for the validation statistics.
